drugset / Trial / NCT02678299
Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1/2 open label study to assess the safety and efficacy of pixantrone in combination with bendamustine, etoposide and , for CD20 positive B-cell lymphomas, rituximab (P\[R\]EBEN), in patients with relapsed aNHL of B- or T-cell phenotype.
Timeline
- Start
- 2016-02
- Primary completion
- 2022-02
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pixantrone | Small molecule | — | — |
| Background | Bendamustine | Small molecule | — | — |
| Background | Etoposide | Small molecule | — | — |
| Background | Rituximab | Monoclonal antibody | — | — |